KNOTUS Co.Ltd - Asset Resilience Ratio
KNOTUS Co.Ltd (278650) has an Asset Resilience Ratio of 0.43% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 278650 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how KNOTUS Co.Ltd's Asset Resilience Ratio has changed over time. See KNOTUS Co.Ltd net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down KNOTUS Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 278650 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩683.20 Million | 0.43% |
| Total Liquid Assets | ₩683.20 Million | 0.43% |
Asset Resilience Insights
- Limited Liquidity: KNOTUS Co.Ltd maintains only 0.43% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
KNOTUS Co.Ltd Industry Peers by Asset Resilience Ratio
Compare KNOTUS Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Aktis Oncology, Inc. Common stock
NASDAQ:AKTS |
Biotechnology | 23.64% |
|
Janux Therapeutics Inc
NASDAQ:JANX |
Biotechnology | 91.79% |
|
Neurotech International Ltd
AU:NTI |
Biotechnology | 0.22% |
|
SynCore Biotechnology Co Ltd
TWO:4192 |
Biotechnology | 2.58% |
|
Uniqure NV
NASDAQ:QURE |
Biotechnology | 10.94% |
|
Jazz Pharmaceuticals plc
F:J7Z |
Biotechnology | 6.34% |
|
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI |
Biotechnology | 0.00% |
|
Altimmune Inc
NASDAQ:ALT |
Biotechnology | 82.06% |
Annual Asset Resilience Ratio for KNOTUS Co.Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for KNOTUS Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 27.83% | ₩46.84 Billion ≈ $31.74 Million |
₩168.33 Billion ≈ $114.07 Million |
-13.15pp |
| 2023-12-31 | 40.97% | ₩70.36 Billion ≈ $47.68 Million |
₩171.71 Billion ≈ $116.37 Million |
-15.39pp |
| 2022-12-31 | 56.36% | ₩97.05 Billion ≈ $65.77 Million |
₩172.19 Billion ≈ $116.69 Million |
+45.38pp |
| 2021-12-31 | 10.98% | ₩10.39 Billion ≈ $7.04 Million |
₩94.63 Billion ≈ $64.13 Million |
-9.11pp |
| 2020-12-31 | 20.09% | ₩14.91 Billion ≈ $10.10 Million |
₩74.22 Billion ≈ $50.29 Million |
-6.24pp |
| 2019-12-31 | 26.33% | ₩16.20 Billion ≈ $10.98 Million |
₩61.53 Billion ≈ $41.70 Million |
+17.56pp |
| 2018-12-31 | 8.78% | ₩3.84 Billion ≈ $2.60 Million |
₩43.74 Billion ≈ $29.64 Million |
-38.63pp |
| 2017-12-31 | 47.40% | ₩15.51 Billion ≈ $10.51 Million |
₩32.72 Billion ≈ $22.17 Million |
+22.52pp |
| 2016-12-31 | 24.88% | ₩4.86 Billion ≈ $3.29 Million |
₩19.53 Billion ≈ $13.23 Million |
-- |
About KNOTUS Co.Ltd
HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug deve… Read more